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Pertussis is a current public-health problem and major cause
of death in children, even in countries with high vaccination
coverage [1,2]. This bacterial respiratory disease is caused by
Bordetella pertussis, but other Bordetella species such as
B. parapertussis, B. bronchiseptica, and B. holmesii can provoke
symptomatology similar to pertussis [3–5]. The World Health
Organization (WHO) estimated that in 2008, about 16 million
cases of pertussis occurred worldwide with about 195,000
deaths, 95% in developing countries [6].
For several decades, the infant-immunization programs with
antipertussis vaccines had been successful in preventing severe
disease. In recent years, however, pertussis has resurged in
different countries with a surprisingly high number of cases
[7]. For example, in Argentina, the number of pertussis reported
cases has increased steadily since 2002, in 2011 quadrupling
those detected in 2006 (4.1 vs. 16 per 100,000 inhabitants) [8].
In 2011, 76 deaths were reported in children under 1 year
(www.snvs.msal.gov.ar [8]). Another example of resurgence
occurred in the US, where the incidence rate in infants with
less than 1 year in 2010–2012 duplicated those in 2002 (125 vs.
60 per 100,000 inhabitants). In this country, incidence rates
were very high in infants but also in 7- to 10-year-old children
and adolescents (13–14 years, http://www.cdc.gov/pertussis/out
breaks/trends.html). Another industrialized country experien-
cing a notable outbreak is the UK, where in 2012 14 infant
deaths were reported (Public Health England; cf. https://www.
gov.uk/government/publications/whooping-cough-pertussis-
statistics, accessed October 2016).
This epidemic in different countries has moved the
scientific community and health professionals to seek an
understanding of this alarming new situation, to identify
the causes [9–11] and review and implement new strate-
gies for the control of pertussis [12]. Several factors appar-
ently contribute to this pertussis-case increase, probably
some occurring at a different weight depending on the
country and the population considered. Nevertheless, a
consensus exists in identifying, as part of the causes of
the epidemic, several factors related to the vaccines cur-
rently in use and the vaccination—e.g. suboptimal cover-
age of the three primary doses, noncompliance with
vaccination-schedule timing (delayed vaccination) [13,14],
the waning of vaccination-conferred immunity [15–17], and
the circulation of a resistant bacterial causative-agent
population resulting from the selection pressure exerted
by mass vaccination [11].
Currently, two types of vaccines against pertussis are in use:
the whole-cell vaccines (wP) constituted by a suspension of
detoxified heat-killed bacteria and acellular vaccines (aP) consist-
ing of purified B. pertussis immunogens. wP was the first devel-
oped against the disease. With the massive use of this vaccine in
the 1950s, the incidence and mortality associated with pertussis
fell to very low levels. Reports on safety concerns in the 1970s,
however, cast doubt on the wP vaccines’ value since they were
associated not only with side effects at the injection site but also
serious systemic reactions [18,19]. These drawbacks and, to a
lesser extent, the low effectiveness of particular wP vaccines
contributed to reducing pertussis-vaccine acceptance in coun-
tries such as the UK, Italy, Ireland, Australia, West Germany,
Russia, Japan and Sweden [19,20].
The widespread apprehension about wP prompted the devel-
opment of acellular vaccines containing purified antigenic-protein
components of B. pertussis (2, 3, or 5 immunogens) [21,22].
Though finally there is no evidence to suggest that wP
vaccines cause severe adverse reactions such as brain damage
or severe neurological disorder, the aP vaccines are more
accepted, especially in industrialized countries where they
have gradually superseded the wP formulations. Currently,
most of the countries of the EU and US use only aP vaccines.
The aP formulations restored people’s confidence in pertussis-
containing vaccines, and infection appeared controlled for
several years. Notwithstanding, during the last two decades,
the epidemiology of pertussis has changed [7,23] with several
major outbreaks occurring, the incidence of which not only
indicated a waning immunity but also demonstrated that the
wP vaccines gave children a more lasting immunity than aP
[24–26]. Furthermore, the risk of pertussis was increased in
school children and adolescents vaccinated exclusively with aP
compared to those receiving only one wP dose [26,27]. This
difference could result from the weaker immune response
induced by aP vaccines characterized mainly by Th2 profiles
[28]. In 2015, the Strategic Advisory Group of Experts on
immunization expressed concern regarding the resurgence
of pertussis in certain industrialized countries despite high aP-
vaccine coverage [29]. The switch from wP to aP for primary
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infant immunization was proposed as at least partially respon-
sible for that resurgence. WHO therefore recommended that
the switch be considered only if, in the national immunization
schedules, large numbers of doses including several boosters
can be assured. Countries currently using aP vaccines may
continue using them, but should consider the need for addi-
tional booster doses and strategies to prevent early-childhood
mortality upon pertussis resurgence.
Within this context, along with optimizing the use of cur-
rent vaccines (i.e. vaccination during pregnancy, cocooning
strategy, etc.), a need to develop new and improved vaccines
is urgent. Because no absolute correlate for protection exists,
the task is therefore difficult. Data from animal models and
human studies, however, indicate that although antibodies
may mediate protection, Th1 and Th17 cellular responses are
responsible for long-lasting protection [28]. To induce or drive
a Th1 and Th17 response, different approaches have already
been proposed [30–32]. Here, I will describe the vaccine can-
didate designed by us.
1. Bases for designing our novel pertussis vaccine
Component vaccines, or subunit vaccines, are particularly
attractive from the standpoint of reduced toxicity, since they
are safer than vaccines constituted by the entire organism,
either dead or attenuated [33]. Despite the advantages in
safety, a fundamental limitation is their inability to stimulate
a strong immune response in vivo when administered alone.
Therefore, to enhance their immunogenicity, they should be
combined with adjuvants, conjugated to polysaccharides, or
formulated in antigen-controlled-release systems [34,35].
Controlled-release technologies have become promising stra-
tegies for protein-immunogen presentation and release, as the
protein immunogens present in these delivery systems have
similar conformations to those of the pathogens; moreover,
they are more readily internalized by antigen-presenting cells.
Some of these controlled-release technologies, however,
require purification steps and the antigen encapsulation that
normally make these approaches costly, especially in develop-
ing countries.
A promising option for replacing the above-mentioned
strategies is the use of outer-membrane vesicles (OMVs)
that naturally contain bacterial surface antigens. Indeed,
two meningitis vaccines containing components derived
from the outer membrane and periplasm of Neisseria menin-
gitidis serogroup B are currently available [36,37]. Though
OMV-containing meningococcal vaccine has been approved
by regulatory agencies, recent work on meningitis B vaccines
shows that OMVs can be modified to yield an OMV product
that is safer and effective [38]. Data on the safety and efficacy
of these vaccines and the knowledge that most Gram-
negative bacteria secrete vesicles naturally make vesicle-
vaccination strategy feasible for other diseases [39]. Within
this context, we designed a new pertussis vaccine based on
OMVs derived from B. pertussis, which can be used as a
combined vaccine with at least tetanus and diphtheria tox-
oids. The OMVs derived from B. pertussis range in size from
approximately 50 to 200 nm in diameter and enclose many
native bacterial antigens within the spherical particles. We
characterized the composition of the pertussis nanoparticles
at >200 protein components—including the virulence factors
pertussis toxin, pertactin, fimbriae, filamentous haemggluti-
nin, and adenylate-cyclase [40,41]. The mean content of the
main B. pertussis protective immunogen, the PTx in OMVs is
15.1 ± 3.2 ng/μg of total OMVs proteins. The biotechnological
process used for obtaining the OMVs contains steps of soni-
cation, centrifugation, and tangential cross-flow filtration.
This process is robust and reproducible. To date, we have
obtained over 40 batches of B. pertussis–derived OMVs.
Similar morphology, size distribution, and presence of sur-
face immunogens identified first by two-dimensional electro-
phoresis associated to matrix-assisted laser desorption
ionization-time-of-flight mass spectrometry analysis and
then by orbitrap technology were observed in all the
obtained batches [40]. It is interesting to note that the pre-
sence of a high number of immunogens in the vaccine for-
mulation is essential since they may avoid the sufficient
selective pressure conferred by a single or a few protective-
vaccine antigens.
To characterize functionally the OMV-based vaccine, we
formulated the OMVs with tetanus and diphteria toxoids
[41,42]. The safety of this vaccine was evaluated by a mouse
weight-gain test and the murine and human whole-blood IL-
6-release assays. The latter assay that evaluates the levels of IL-
6 as indicator of proinflammatory response was described
previously for Neisseria vaccines [43]. The OMV vaccine pre-
pared by us fulfilled the WHO criteria for safety in the weight-
gain test. Results from mouse and human whole-blood assays
also demonstrated that the wP exhibits a higher endotoxic
activity than the commercial aP- and OMV-based vaccines [44].
In agreement with these results, we determined that the
lipopolysaccharide content in the OMV-based vaccines is at
least 50 times lower than the commercial wP.
The protection capability of the OMV-based vaccine was
evaluated by the mouse-intranasal-challenge model
[41,42,45]. Using this model, we detected that OMV-based
vaccines are effective against strains expressing vaccine/
reference type ptxP1, ptxA2, prn1, fim3-1 (Bp Tohama phase
I) and ptxP4, ptxA4, prn6, fim3-1 (Bp18323), and non-vaccine-
type alleles, ptxP3, ptxA1, prn2, fim3-2 (circulating strain
Bp106) [42], including pertactin-negative isolates whose pre-
valence has increased in recent years in countries that only
use aP in their calendars [46]. In contrast, commercial aP
vaccine used in a dose in which PTx content was equivalent
to OMV-based vaccine, showed little protection effect against
all genotypes tested. wP vaccine used in 1/20 of human dose
also exhibited lower protective capacity against ptxP3, ptxA1,
prn2, and fim3-2 (circulating strain Bp106).
As wP, our vaccine candidate induced a mixed Th1-Th17-Th
2 profile and conferred a long-term protection in the murine
model [42,44]. In contrast, commercial aP administered with
alum as the adjuvant induced Th2 and Th17 cells, but weak
Th1 responses. The long-term protection for the meningococ-
cal vaccine based on OMVs is currently under discussion. It
was reported that the duration of antibody titers induced by
the commercial Bexsero vaccine appeared shorter than that
following MenC conjugate vaccination [47]. This seems not the
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case for OMVs pertussis vaccine since memory response seems
to be associated with such mixed Th1-Th17-Th2 profile
induced. We recently detected that the transfer of spleen
cells from mice immunized with our OMV-based–vaccine-
induced protection in recipient mice (manuscript in prepara-
tion). Moreover, OMV vaccination also induced, as did wP, a
robust antibody response (total IgG titer: 4710.00 ± 723.91 for
wP and 1387.41 ± 221.67 for OMV-based vaccine) with a high
IgG2a/IgG1 ratio. OMV-induced antibodies also transferred
protection against B. pertussis infection. Antibodies may confer
protection by several mechanisms. We observed that
B. pertussis was efficiently opsonized by OMV-induced antibo-
dies. The antibody responses induced by OMVs were directed
against GroEL, outer-membrane-protein complex but also per-
tussis toxin, fimbriae, and pertactin [44].
OMVs could also be used in combination with commercial
aP vaccines to direct their immune response to a Th1 profile
without affecting the protective capacity of both vaccines. We
also obtained excellent protection against B. parapertussis [48]
and B bronchiseptica with OMVs derived from those pathogens
(manuscript in preparation).
In summary, our formulation based on OMVs derived from
B. pertussis contains a greater number of immunogens and
conformations close to those found in the causal agents than
the commercial aP vaccines. Moreover, OMVs are 10 times
smaller in diameter than whole bacteria, thus possibly increas-
ing the exposure to different cell types. OMVs may further-
more reach immune cells deeper in the tissues that are less
accessible for the whole bacteria or large alum particles to
induce an immune response [49]. Our vaccine formulation is
less toxic than wP and likewise attractive from an economic
standpoint. The final cost per dose would be lower than that
of the existing acellular vaccines based on several purified
protein immunogens one by one—a detail clearly impacting
the final cost of the vaccine. With our OMVs, a single proce-
dure is necessary for their production. Furthermore, our OMV
platforms evidence a promising protection spectrum for
developing new vaccines against other Bordetella species [48].
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